
Vericel (VCEL) Stock Forecast & Price Target
Vericel (VCEL) Analyst Ratings
Bulls say
Vericel Corp's recent performance highlights a robust growth trajectory, with NexoBrid hospital orders surging 40% quarter-over-quarter and an annual increase in the burn care franchise of 22% year-over-year, reaching $39.9 million for FY2024. Management's commitment to expand the burn care salesforce is anticipated to further enhance growth, projecting an 8.3% increase for 2025, while MACI also demonstrated strong momentum, achieving $68.3 million in 4Q24, a 21% increase from the previous year. With significant upcoming product launches and a positive trend in MACI implant metrics, Vericel is positioned for accelerated revenue growth and an expected profit inflection, indicative of its potential for sustained market performance.
Bears say
Vericel Corporation reported preliminary revenue results that fell short of expectations, notably with lower contributions from its products, specifically Epicel and NexoBrid, indicating potential weakened demand. The company's fourth-quarter results showed a top-line miss, coming in at $75.4 million, which was below earlier forecasts and raises concerns about growth prospects amid potential end-market weaknesses and competitive dynamics. Key risks identified include recession impacts, operational disruptions, and underperformance in patient treatment conversions, all contributing to a cautious outlook on the company's short-term financial performance.
This aggregate rating is based on analysts' research of Vericel and is not a guaranteed prediction by Public.com or investment advice.
Vericel (VCEL) Analyst Forecast & Price Prediction
Start investing in Vericel (VCEL)
Order type
Buy in
Order amount
Est. shares
0 shares